Also in the second half of 2018, we plan to submit two Investigational New Drug Applications to the FDA, for ADVM-022 in wet AMD and ADVM-053 in hereditary angioedema, as we prepare to advance these two additional gene therapies into the clinic." Recent Progress 2018 Outlook - Planned Pipeline Milestones ADVM-043 for A1AT Deficiency ADVM-022 for wAMD ADVM-053 for Hereditary Angioedema (HAE) Upcoming Events Financial Results for the Three Months Ended March 31, 2018 About Adverum Biotechnologies, Inc. Adverum is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD).